Does Blue Cross Blue Shield of Texas Cover Victoza?

What Is Victoza and Why Does Coverage Matter?

Victoza is the brand name for liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Novo Nordisk. The FDA approved it on January 25, 2010, for glycemic control in adults with type 2 diabetes. 1 A subsequent label update recognized its cardiovascular benefit after the LEADER trial demonstrated a statistically significant 13% reduction in major adverse cardiovascular events (MACE) among high-risk patients compared with placebo. 2

Coverage decisions matter because the list price of Victoza runs approximately $900 to $1,100 per month without insurance. For patients who need it, that price is prohibitive. Understanding exactly how BCBS Texas evaluates the drug gives you the best chance of getting it approved and keeping your out-of-pocket cost manageable.

How GLP-1 Drugs Are Classified Differently Than Older Diabetes Agents

GLP-1 receptor agonists sit in a different clinical and formulary category than older oral agents like metformin or sulfonylureas. They are injectable, brand-name, and typically placed on higher formulary tiers. The American Diabetes Association's 2024 Standards of Care specifically recommend adding a GLP-1 receptor agonist for patients who need additional glucose lowering beyond metformin, particularly those with atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. 3

That clinical guideline language is directly useful during a prior authorization appeal, because it establishes medical necessity grounded in evidence-based standards of care.

Liraglutide vs. Semaglutide: Why Your Plan May Prefer One Over the Other

BCBS Texas plans sometimes place semaglutide (Ozempic) on a more favorable tier than liraglutide (Victoza) because of negotiated rebates. If your prescriber writes for Victoza and your plan prefers Ozempic, you may face a non-preferred brand denial. Clinically, the SUSTAIN-6 trial showed semaglutide 0.5 mg and 1.0 mg reduced MACE by 26% vs. Placebo (HR 0.74, 95% CI 0.58-0.95, P<0.001 for non-inferiority). 4 Your prescriber can request a formulary exception if there is a documented clinical reason to use liraglutide specifically, such as prior tolerability issues with semaglutide.

BCBS Texas Plan Types and How They Treat Victoza Differently

Blue Cross Blue Shield of Texas is not a single plan. It is a portfolio of products, and each product has its own formulary. The four main plan types a Texas resident might hold are: an employer-sponsored fully insured commercial plan, a self-funded employer plan (where BCBS Texas only administers claims), a Marketplace (ACA) plan, and a Medicare Advantage plan.

Commercial Employer Plans

Most fully insured commercial BCBS Texas plans place Victoza on Tier 3 (preferred brand). Tier 3 co-pays typically run $50 to $100 for a 30-day supply at in-network retail pharmacies, and $90 to $200 for a 90-day supply at mail-order. Prior authorization is required on the vast majority of these plans.

The formulary can change January 1 of each plan year. Always verify the current year's formulary at the BCBS Texas online drug lookup tool or call the member services number on the back of your insurance card.

Self-Funded Employer Plans

Self-funded plans follow a formulary set by the employer, not by BCBS Texas directly. This means coverage rules vary significantly. Some large Texas employers exclude all GLP-1 drugs from their formulary entirely; others cover them with the same PA criteria as fully insured plans. If you are on a self-funded plan, your plan documents (the Summary Plan Description) govern coverage, not state insurance mandates.

ACA Marketplace Plans

ACA plans sold through the Texas marketplace must cover essential health benefits but are not required by federal law to cover every branded drug. Victoza coverage on Marketplace plans depends entirely on the specific silver, gold, or platinum tier plan you selected. Some BCBS Texas Marketplace plans place liraglutide on Tier 4 (non-preferred brand) with co-insurance of 30-50% after the deductible, which can mean $300 or more per month even with insurance. 5

Medicare Advantage Plans

BCBS Texas Medicare Advantage plans have their own Part D formularies. Medicare Part D is required to cover at least two drugs in every drug class, including GLP-1 receptor agonists, but the specific agents covered vary. As of 2025, most BCBS Texas Medicare Advantage Part D formularies cover liraglutide at Tier 3 or Tier 4, with a typical patient co-pay of $47 to $95 during the initial coverage phase. 6 The Extra Help (Low Income Subsidy) program can reduce that cost to as little as $4.50 per month for qualifying beneficiaries. 7

Prior Authorization: The Exact Requirements BCBS Texas Uses

Prior authorization (PA) is the step-by-step review BCBS Texas conducts before agreeing to pay for Victoza. Getting it right the first time saves weeks of delay.

Standard PA Criteria

BCBS Texas PA criteria for Victoza on commercial plans generally include all of the following:

• A confirmed diagnosis of type 2 diabetes (ICD-10 code E11.x), not type 1.
• An HbA1c of 8.0% or higher at the time of the request, or documented inadequate glycemic control despite optimized oral therapy.
• Evidence that the member has tried and failed, or has a contraindication to, at least one generic first-line agent. Metformin 1,000 mg twice daily for at least 90 days is the most common required trial.
• The prescribing physician must be the patient's treating provider for diabetes management, not a specialist writing a one-time consultation note.

The FDA's prescribing information confirms liraglutide's indication for adults with type 2 diabetes as an adjunct to diet and exercise. 8 Referencing that label in your PA request anchors the clinical necessity in regulatory language.

Cardiovascular Indication

After LEADER (N=9,340), the FDA expanded the Victoza label to include reduction of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. 9 BCBS Texas PA criteria for the CV indication typically require documentation of established ASCVD (prior MI, stroke, or symptomatic peripheral arterial disease) in addition to the diabetes diagnosis. Providing a cardiology note or relevant procedure records alongside the PA request significantly speeds approval.

Documentation Your Prescriber Should Submit

Your prescriber's PA submission should include: the most recent HbA1c lab result with the date, a medication history showing the prior generic trial, the relevant ICD-10 diagnosis codes, and, if applicable, a cardiovascular history summary. Incomplete documentation is the single most common reason for initial PA denial. A 2022 analysis published in JAMA found that 94% of physicians reported that PA requirements delay access to necessary care, and 80% said PA caused treatment abandonment. 10

What Happens if BCBS Texas Denies Coverage?

Denial is not the end. Federal and Texas state law give you specific appeal rights.

First-Level Internal Appeal

You have the right to request an internal appeal within 180 days of receiving a denial notice. For a standard appeal, BCBS Texas has 30 days (for non-urgent cases) to respond. For urgent situations, an expedited appeal must be decided within 72 hours. Submit a letter from your prescriber explaining why Victoza is medically necessary, referencing the ADA 2024 Standards of Care 11 and the LEADER trial cardiovascular outcome data.

External Review

If your internal appeal is denied, you can request an independent external review. Texas Department of Insurance regulations require BCBS Texas to honor external review decisions. An independent review organization (IRO) will evaluate whether the denial was consistent with medical evidence, not just with the plan's formulary preferences.

Formulary Exception Request

Separate from the PA appeal, you can request a formulary exception, asking BCBS Texas to cover Victoza at a lower tier or to cover it at all if it is excluded. The exception request must include a prescriber statement that no other formulary drug is clinically appropriate for the member.

Cost Reduction Strategies When Coverage Is Partial or Denied

Even partial coverage leaves many patients with a significant monthly cost. These strategies can reduce what you actually pay.

Novo Nordisk Co-Pay Assistance Card

Novo Nordisk offers a co-pay savings card for commercially insured patients that may reduce the Victoza co-pay to as low as $25 per month (terms subject to change; visit the Novo Nordisk patient assistance page for current eligibility). This program is not available to Medicare or Medicaid beneficiaries. 12

Novo Nordisk Patient Assistance Program

Uninsured or underinsured patients with household income below 400% of the federal poverty level may qualify for the Novo Nordisk Patient Assistance Program, which provides Victoza at no cost. Documentation of income and lack of adequate coverage is required. 13

GoodRx and Pharmacy Discount Programs

GoodRx and similar discount programs occasionally reduce Victoza's cash price to $650 to $800 per month at certain Texas pharmacies, which is below the list price but still significant. These programs do not combine with insurance; you use one or the other.

Therapeutic Substitution With Plan-Preferred GLP-1 Agents

If your plan covers a different GLP-1 receptor agonist (such as Ozempic, Trulicity, or Rybelsus) at a lower tier, your prescriber can evaluate whether that agent is clinically appropriate for you. Dulaglutide (Trulicity) demonstrated non-inferiority to liraglutide in the AWARD-6 trial (HbA1c reduction of 1.42% vs. 1.36% at 26 weeks, P<0.001 for non-inferiority) 14 and may be covered at Tier 2 on some BCBS Texas plans.

The Clinical Evidence That Supports Medical Necessity Arguments

When appealing a denial, your strongest tool is peer-reviewed clinical evidence. These are the key trials to reference.

LEADER Trial: Cardiovascular Outcomes

LEADER enrolled 9,340 adults with type 2 diabetes at high cardiovascular risk and followed them for a median of 3.8 years. Liraglutide 1.8 mg daily reduced the primary composite endpoint (CV death, non-fatal MI, non-fatal stroke) by 13% compared with placebo (HR 0.87, 95% CI 0.78-0.97, P<0.001 for non-inferiority and P=0.01 for superiority). 15 All-cause mortality was also significantly reduced (HR 0.85, P=0.02).

The table below summarizes how to match the LEADER trial's enrollment criteria to a PA appeal for a specific patient profile.

| Patient Characteristic | LEADER Enrollment Criterion | How to Document for PA | |---|---|---| | Age 50+ with established CVD | Prior MI, stroke, or revascularization | Submit cardiology or hospital records | | Age 60+ with CVD risk factors only | 2+ risk factors (hypertension, dyslipidemia, etc.) | Submit primary care notes with risk factor list | | HbA1c at baseline | Mean 8.7% at randomization | Submit recent lab with date | | Prior medication use | ~75% on metformin at baseline | Include medication history |

HbA1c and Weight Effects

The SCALE Diabetes trial (N=846) tested liraglutide 3.0 mg (the Saxenda dose, not the Victoza dose) for weight loss in type 2 diabetes, but the 1.8 mg Victoza dose also produces meaningful weight reduction. In LEADER, patients on liraglutide lost a mean of 2.3 kg vs. 1.3 kg gained in the placebo arm at 36 months. 16 For patients with obesity-related type 2 diabetes, documenting this dual benefit can strengthen the PA case.

Renal Protection Data

A prespecified secondary analysis of LEADER showed liraglutide reduced the composite renal outcome (new-onset persistent macroalbuminuria, persistent doubling of serum creatinine, ESRD, or renal death) by 22% (HR 0.78, P=0.003). 17 For patients with early diabetic kidney disease, citing this data adds a nephrology dimension to the medical necessity argument.

How Texas State Law Affects Your Coverage Rights

Texas has consumer protection laws that intersect with insurance coverage for prescription drugs.

Texas Department of Insurance Step Therapy Protections

Texas Insurance Code Chapter 1369 limits the use of step therapy (requiring patients to try and fail a less expensive drug first) for certain conditions. While the law does not specifically mandate GLP-1 coverage, it does require that step therapy protocols be grounded in clinical evidence and that exceptions be granted within 72 hours when the treating physician documents clinical necessity. 18 This is directly relevant if BCBS Texas requires you to try a different GLP-1 before Victoza.

ACA Prohibition on Retroactive Denial

If BCBS Texas approves your PA and you begin using Victoza, it cannot retroactively deny coverage for the approved period without a finding of fraud or material misrepresentation. This protection is established under ACA Section 2712. 19

Practical Step-by-Step Action Plan for Getting Victoza Covered

This is what to do, in order, starting from your first prescriber visit.

Step 1: Confirm Your Plan's Formulary Before the Prescription Is Written

Log into your BCBS Texas member portal or call the pharmacy benefits number on your card. Ask specifically: Is liraglutide (Victoza, NDC 00169-4060-12) on my formulary? What tier? Is prior authorization required? Write down the date, time, and name of the representative.

Step 2: Have Your Prescriber Submit a Complete PA Request

Give your prescriber the checklist from the "Documentation" section above. Incomplete PA submissions are the primary cause of denial. A 2023 survey by the American Medical Association found that prior authorization submissions lacking even one required document had a denial rate 3.4 times higher than complete submissions. 20

Step 3: Enroll in the Novo Nordisk Co-Pay Program Simultaneously

While the PA is pending, have your prescriber's office enroll you in the co-pay assistance program. If the PA is approved, you will already have the savings card ready. If denied, the enrollment data is not wasted; it transfers to an appeal period.

Step 4: Request Peer-to-Peer Review if Initially Denied

If your PA comes back denied, your prescriber has the right to request a peer-to-peer review with the BCBS Texas medical director who issued the denial. This phone call, typically 15 to 20 minutes, allows the prescriber to present clinical context not captured in the written submission. Peer-to-peer reviews reverse approximately 30% of initial GLP-1 denials based on prescriber-reported outcomes across multiple practice settings.

Step 5: File a Formal Appeal With Full Clinical Package

Attach the LEADER trial abstract, the ADA 2024 guideline recommendation text, your most recent HbA1c, and a signed letter of medical necessity from your prescriber. Send everything by certified mail and keep a copy.

The ADA's 2024 Standards of Care state directly: "For patients with type 2 diabetes and established cardiovascular disease, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended." 21 Quoting that exact language in an appeal letter forces BCBS Texas to address why denial is consistent with evidence-based medicine.

Monitoring and Ongoing Coverage Once Victoza Is Approved

PA approvals are typically granted for 12 months and require renewal. Set a calendar reminder 60 days before your approval expiration date so your prescriber can submit the renewal PA with updated labs. If your HbA1c has improved significantly (to below 7.5%), some plans may question whether the drug is still necessary. Your prescriber should document that discontinuation risks glycemic rebound and loss of cardiovascular protection.

The FDA label for Victoza recommends assessing HbA1c every 3 months until stable, then every 6 months. 22 Keeping those lab records current not only guides clinical management but also provides continuous documentation for PA renewals.

Novo Nordisk has not filed an application for a Victoza biosimilar as of mid-2025, so no lower-cost interchangeable product is expected in the near term. The FDA's biosimilar database confirms no liraglutide biosimilar has received approval. 23